FYERS
Home
/
Stocks
/
Results
/
Anlon Healthcare Results

Anlon Healthcare Results

Financial overview

CAGR%
Sales
Profits
Returns
ROE
10Y5Y3YTTM
---43%
---42%
---91%
22%22%22%19%

Peer Comparison

Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
LAURUSLABS
ZYDUSLIFE
DRREDDY
CIPLA
MANKIND
AUROPHARMA
LUPIN
AHCL
PriceM.Cap (₹)PE RatioEPS (₹)EV/EBITDAAnnual PAT
1,773.4₹425150 Cr38.778.2958.23₹11479 Cr
10,037.5₹266265 Cr91.0334.04128.41₹2568 Cr
4,738.5₹176301 Cr8314.04106.21₹2163 Cr
2,323.8₹125352 Cr93.568.1733.94₹889 Cr
1,188.1₹123591 Cr27.399.4262.53₹5040 Cr
1,374₹114351 Cr40.8411.0859.2₹4196 Cr
1,402₹112474 Cr38.8210.8652.6₹3879 Cr
2,537.9₹102315 Cr45.6217.2376.26₹1913 Cr
1,705₹97757 Cr26.3317.9596.84₹3505 Cr
2,008.6₹92007 Cr16.6430.95154.35₹5333 Cr
26.66₹1349 Cr47.310.250.57₹29 Cr

Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Sep 2026Jun 2026Mar 2026Sep 2025Jun 2025Mar 2025
₹106 Cr₹88 Cr₹51 Cr₹52 Cr₹33 Cr₹49 Cr
₹5 L₹6 L₹1 L₹3 L₹1 L₹4 L
₹106 Cr₹88 Cr₹51 Cr₹52 Cr₹33 Cr₹49 Cr
₹81 Cr₹73 Cr₹36 Cr₹39 Cr₹27 Cr₹33 Cr
₹25 Cr₹16 Cr₹15 Cr₹14 Cr₹6 Cr₹17 Cr
₹86 L₹93 L₹57 L₹84 L₹82 L₹91 L
₹23 Cr₹14 Cr₹14 Cr₹12 Cr₹5 Cr₹15 Cr
₹17 Cr₹8 Cr₹11 Cr₹9 Cr₹4 Cr₹17 Cr

Balance Sheet

Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Minority Interest
Secured Loans
Unsecured Loans
Deferred Tax Assets / Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
Mar 2026Mar 2025
——
₹53 Cr₹40 Cr
₹177 Cr₹41 Cr
₹177 Cr₹41 Cr
₹230 Cr₹80 Cr
₹25 Cr₹0
₹6 Cr₹5 Cr
₹4 L₹34 Cr
₹5 Cr₹2 Cr
₹37 L₹24 L
₹12 Cr₹41 Cr
——
₹42 Cr₹20 Cr
₹14 Cr₹4 Cr
₹38 Cr₹28 Cr
₹14 Cr₹8 Cr
₹108 Cr₹60 Cr
₹374 Cr₹181 Cr
₹25 L₹0
₹44 Cr₹67 Cr
——
₹84 Cr₹36 Cr
₹26 Cr₹13 Cr
₹58 Cr₹23 Cr
₹98 L₹0
₹98 L₹0
₹7 Cr₹0
₹66 Cr₹23 Cr
——
₹1 L₹91 L
₹113 Cr₹50 Cr
₹104 Cr₹75 Cr
₹4 Cr₹1 Cr
₹1 Cr₹1 Cr
₹86 Cr₹30 Cr
₹308 Cr₹158 Cr
₹201 Cr₹98 Cr
₹374 Cr₹181 Cr
₹43₹20
₹4₹2

Cash Flow

Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Closing Cash & Cash Equivalent
Mar 2026Mar 2025
₹43 Cr₹27 Cr
₹5 Cr-₹56 L
-₹122 Cr-₹54 Cr
-₹75 Cr-₹28 Cr
-₹79 Cr-₹23 Cr
-₹36 Cr₹3 Cr
₹119 Cr₹19 Cr
₹3 Cr-₹82 L
₹1 Cr₹2 Cr
₹4 Cr₹1 Cr

Fundamental Ratios

Consolidated
Standalone
Empty box

No results found

Share Price Live Stats

Open (₹)25.31
Volume (₹)50.53 L
High (₹)26.67
Upper Circuit26.67
Low (₹)25.00
Lower Circuit24.13
Prev Close25.40
52W High (₹)37.24
Price26.66
52W Low (₹)10.37

Share Market Cap & Key Ratios Overview

M.Cap (₹)1348.99 Cr
Div. Yield (%)0.00
PE Ratio47.31
Debt to Equity0.19
Price to Book2.57
Book Value4.33
EPS (TTM)0.54
Face Value2.00
ROE (%)18.73

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
LAURUSLABSNSE
ZYDUSLIFENSE
DRREDDYNSE
CIPLANSE
MANKINDNSE
AUROPHARMANSE
LUPINNSE
AHCLNSE
LTP
1W Low
1W High
Market cap (₹)
1773.4-4.3 (-0.24%)
1722
1810.40
4,25,150Cr
10037.5+257.5 (2.63%)
9863
10067
2,66,265Cr
4738.5+125.1 (2.71%)
4553
4738.50
1,76,301Cr
2323.8-81.7 (-3.40%)
2252.40
2441.90
1,25,352Cr
1188.1-57.4 (-4.61%)
1182.40
1266.60
1,23,591Cr
1374+22 (1.63%)
1336.70
1376.70
1,14,351Cr
1402+23.1 (1.68%)
1364.60
1402
1,12,474Cr
2537.9+45.1 (1.81%)
2457.90
2540
1,02,315Cr
1705+23.6 (1.40%)
1656.20
1724.60
97,757Cr
2008.6-2.4 (-0.12%)
1988.90
2062.10
92,007Cr
26.66+0.77 (2.97%)
24.60
26.67
1,349Cr

Anlon Healthcare Ltd Annual Results Key Takeaways

Operating profit (before other income, interest and exceptional items) was ₹15.65Cr; with other income of ₹6Lakh, profit before interest and tax came to ₹14.58Cr. Interest expense was ₹92.5Lakh; PBT before exceptional items stood at ₹13.66Cr. Cost mix (full year): raw materials ₹149.31Cr; employee cost ₹5.54Cr; depreciation ₹1.07Cr; other expenses ₹71.97Cr. Basis: consolidated annual results.

Anlon Healthcare Ltd Quaterly Results Key Takeaways

Operating profit (before other income, interest and exceptional items) was ₹15.65Cr; with other income of ₹6Lakh, profit before interest and tax came to ₹14.58Cr. Interest expense was ₹92.5Lakh, taking profit before tax to ₹13.66Cr.